Previous close | 915.20 |
Open | 915.00 |
Bid | 946.75 x 0 |
Ask | 955.55 x 0 |
Day's range | 914.35 - 955.75 |
52-week range | 356.75 - 955.75 |
Volume | |
Avg. volume | 204,378 |
Market cap | 766.128B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 46.59 |
EPS (TTM) | N/A |
Earnings date | 06 Aug 2019 - 10 Aug 2019 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).